Radioimmunotherapy in Non-Hodgkin’s Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar

The development of monoclonal antibodies has dramatically changed the outcome of patients with non-Hodgkin’s lymphoma (NHL), the most common hematological malignancy. However, despite the satisfying results of monoclonal antibody treatment, only few NHL patients are permanently cured with sing...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Christos Sachpekidis, David B. Jackson, Theodoros G. Soldatos
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2019-09-01
coleção:	Pharmaceuticals
Assuntos:	non-Hodgkin’s lymphoma radioimmunotherapy <sup>90</sup>Y-ibritumomab tiuxetan (Zevalin), <sup>131</sup>I-tositumomab (Bexxar), FDA’s Adverse Event Reporting System (FAERS), VigiBase
Acesso em linha:	https://www.mdpi.com/1424-8247/12/4/141
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!